Complement dependent cytotoxicity (CDC) activity of a humanized anti Lewis-Y antibody: FACS-based assay versus the 'classical' radioactive method-Qualification, comparison and application of the FACS-based approach

Journal of Pharmaceutical and Biomedical Analysis

Volumn 49, Issue 4, 2009, Pages 1014-1020

  Nechansky, A ^a   Szolar, O H J ^b   Siegl, P ^a   Zinoecker, I ^b   Halanek, N ^a   Wiederkum, S ^c   Kircheis, R ^a  

^a Vela pharm Entwicklung u Laboranalytik GmbH   (Austria)

^b Onepharm Research and Development GmbH   (Austria)

^c Babraham Research Campus   (Austria)

Author keywords

CDC; FACS; Lewis Y; Potency; Qualification

Indexed keywords

CHROMIUM 51; COMPLEMENT; IMMUNOGLOBULIN FC FRAGMENT; LEWIS Y ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IGN311; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACCURACY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG STABILITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOACTIVITY; REPRODUCIBILITY; SKBR3 CELL; STATISTICAL ANALYSIS; STORAGE TEMPERATURE;

ALGORITHMS; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL SURVIVAL; COLORING AGENTS; COMPLEMENT SYSTEM PROTEINS; DATA INTERPRETATION, STATISTICAL; FEMALE; FLOW CYTOMETRY; HUMANS; LEWIS BLOOD-GROUP SYSTEM; LINEAR MODELS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 62849128991     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.01.029     Document Type: Article

References (22)

1. Adams G.P., and Weiner L.M. Nature 23 (2005) 1147-1157
2. Couriel D., Saliba R., Hicks K., Ippoliti C., de Lima M., Hosing C., Khouri I., Andersson B., Gajewski J., Donato M., Anderlini P., Kontoyiannis D.P., Cohen A., Martin T., Giralt S., and Champlin R. Blood 104 (2004) 649-654
3. Mihara M., Kasutani K., Okazaki M., Nakamura A., Kawai S., Sugimoto M., Matsumoto Y., and Ohsugi Y. Int. Immunopharmacol. 5 (2005) 1731-1740
4. Klinger M., Farhan M., Just H., Drobny H., Himmler G., Loibner H., Mudde G.C., Freissmuth M., and Sexl V. Cancer Res. 64 (2004) 1087-1093
5. Di Gaetano. J. Immunol. 171 (2003) 1581-1587
6. Johnson P., and Glennie M. Semin. Oncol. 30 (2003) 3-8
7. Vogel C., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., and Stuwart S.J. Eur. J. Cancer 37 (2001) S25-S29
8. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., and Presta L.G. J. Biol. Chem. 276 (2001) 6591-6604
9. Hezareh M., Hessell A.J., Jensen R.C., Van De Winkel J.G.J., and Parren P.W.H.I. J. Virol. 75 (2001) 12161-12168
10. Gelderman K.A., Tomlinson S., Ross G.D., and Gorter A. Trends Immunol. 25 (2004) 158-164
11. Co M.S., Baker J., Bednarik K., Janzek E., Neruda W., Mayer P., Plot R., Stumper B., Vasquez M., Queen C., and Loibner H. Cancer Res. 56 (1996) 1118-1125
12. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, February 28, 1997.
13. Guideline for Industry ICH Q5C. 1996. Quality of biotechnological products: stability testing of biotechnological/biological products.
14. Chirino A.J., and Mire-Sluis A. Nature Biotechnol. 22 (2004) 1383-1391
15. International Conference on Harmonisation Guidance on Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biologics Products. 1999. Federal Register 64:44928.
16. D.V. Oruzio, G. Waxenecker, C. Aulmann, M. Sandherr, G.C. Mudde, M. Schuster, N. Eller, A. Mayer, A. Nechansky, S. Stranner, G. Himmler, R. Kircheis, H. Loibner, G. Schlimok, Clin. Cancer Res., submitted for publication.
17. Decker T., and Lohmann-Mattes M.L. J. Immunol. Meth. 115 (1988) 61-69
18. Korzeniewski C., and Callewaert D.M. J. Immunol. Meth. 64 (1983) 313-320
19. Findlay J.W.A., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., and Bowsher R.R. J. Pharm. Biomed. Anal. 21 (2000) 1249-1273
20. van der Kolk L.E., Grillo-López A.J., Baars J.W., Hack C.E., and van Oers M.H. Br. J. Haematol. 115 (2001) 807-811
21. Oruzio D.V., Aulmann C., Eller N., Mudde G., Obwaller A., Waxenecker G., Scheiber O., Stranner S., and Schlimok G. V 22. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 14S (2004) 2624
22. Guidance for Industry Q1A Stability Testing of New Drug Substances and Products. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 2001.